Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

GBT Global Blood Therapeutics

Watchlist
63.840
+15.850+33.03%
Close 08/05 16:00 ET
63.84000.00%
Pre Mkt Price 08/08 04:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
73.020
Open
47.410
Turnover
895.62M
Low
46.572
Pre Close
47.990
Volume
13.98M
Market Cap
4.16B
P/E(TTM)
Loss
52wk High
73.020
Shares
65.10M
P/E(Static)
Loss
52wk Low
21.650
Float Cap
3.36B
Bid/Ask %
0.00%
Historical High
87.540
Shs Float
52.61M
Volume Ratio
5.48
Historical Low
12.240
Dividend TTM
--
Div Yield TTM
250
P/B
31.01
Dividend LFY
--
Div Yield LFY
391.60%
Turnover Ratio
26.57%
Amplitude
55.11%
Avg Price
64.081
Lot Size
1
Float Cap
3.36B
Bid/Ask %
0.00%
Historical High
87.540
Shs Float
52.61M
Volume Ratio
5.48
Historical Low
12.240
Dividend TTM
--
P/B
31.01
Dividend LFY
--
Turnover Ratio
26.57%
Amplitude
55.11%
Avg Price
64.081
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
CEO: Love M.D., Ted W.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top